Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy produces an average weight loss of 15–22% body weight in clinical trials, yet roughly 30% of patients experience minimal response or significant side effects. The reason lies not in the medication's effectiveness, but in individual genetic differences that determine how your body processes GLP-1 compounds. PlexusDx uses precision genetic testing to match you with the right therapy.

Why Wegovy Works Better for Some Than Others

Wegovy's active ingredient, semaglutide, works by activating the GLP-1 receptor in your brain to reduce hunger and slow stomach emptying. However, genetic variations in the GLP1R gene (such as rs6923761) affect how strongly your cells respond to this signal. Some people carry variants that reduce receptor sensitivity, meaning they need either a higher dose, a different compound, or a combination therapy to achieve the same weight loss as others.

Additional genetic factors influence appetite control through multiple pathways. The FTO gene (rs9939609 variant) affects how your body regulates fat storage and energy expenditure independent of GLP-1 signaling. The MC4R gene (rs17782313) controls satiety signals in your hypothalamus. When these pathways don't work efficiently with semaglutide alone, patients often plateau or experience diminishing returns over time, leading them to believe the medication has stopped working.

Real-world data shows that patients who switch to tirzepatide (a dual GLP-1 and GIP receptor agonist) after poor semaglutide response see significantly better outcomes. This is because tirzepatide activates an additional receptor pathway—the GIPR (rs1800437 variant)—that semaglutide does not target. Without knowing your genetic profile, you may spend months on an ineffective therapy when a better option exists.

Personalized GLP-1 Therapy Beyond Brand-Name Medications

Brand-name medications like Wegovy come in standardized doses designed for the average patient, not for your individual biology. PlexusDx offers compounded semaglutide and tirzepatide from licensed 503A compounding pharmacies, providing flexibility to adjust formulation and dosage based on your genetic insights and response. Because PlexusDx pricing remains flat regardless of dose level, your dose may need to go up—but your price won't.

Compounded medications from PlexusDx start at $149/month for semaglutide injection and $249/month for tirzepatide injection, with no insurance required and HSA/FSA eligibility. For patients who prefer oral delivery, oral semaglutide begins at $249/month and oral tirzepatide at $279/month. PlexusDx also offers GLP-Squared, a dual-compound injection combining semaglutide and tirzepatide in one formulation, starting at $249/month for injection and $369/month for oral.

The Microdose GLP-1 Protocol at $129/month flat represents the most accessible entry point for patients exploring GLP-1 therapy or managing mild-to-moderate weight loss goals. All products are available across all 50 states with no membership fees, making precision-guided weight loss available regardless of geography or insurance status.

The Precision Peptide Genetic Test: Know Your Metabolism

PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month of treatment) analyzes 14 metabolic pathways and 49 peptide-related genes to reveal how your body responds to different GLP-1 compounds. This test is distinct from standard pharmacogenomic panels—it focuses specifically on peptide-pathway genetics, including the four key variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) that predict your response to semaglutide, tirzepatide, and combination therapies.

Your genetic results guide initial therapy selection and inform future adjustments. If your profile shows reduced GLP1R sensitivity but normal GIPR function, starting with tirzepatide or GLP-Squared may produce faster results than semaglutide alone. If your FTO or MC4R variants suggest metabolic resistance, your PlexusDx clinical team may recommend combination therapy or a specific dosing protocol tailored to your peptide pathways. Over 150 individual genetic insights inform personalized treatment planning.

Patients who receive genetic-guided therapy achieve measurable weight loss within 4–8 weeks compared to 8–12 weeks on empirical dosing. This acceleration stems from starting the medication most likely to work for your biology, reducing trial-and-error cycles and improving adherence through faster, visible results.

Making the Switch: From Wegovy to Precision-Guided GLP-1 Care

If Wegovy did not deliver expected weight loss or caused unmanageable side effects, the most common next step is either dose escalation or compound switching—but most patients don't know which option will work better. PlexusDx streamlines this decision by starting with your genetic profile and clinical history. Your first month on any PlexusDx medication allows your body to adjust while your genetic test results return; by month two, your therapy may be optimized based on your unique peptide pathways.

Switching from Wegovy to a PlexusDx compounded GLP-1 therapy is straightforward: complete a brief telehealth consultation, choose your starting medication and formulation (injection or oral), and begin care. PlexusDx does not require prior insurance approval, workplace documentation, or weeks of waiting. Add the Precision Peptide Genetic Test in month one to unlock personalized refinement by month two, ensuring your therapy matches your biology rather than a one-size-fits-all formula.

Patient outcomes after switching to genetically-guided therapy show an average additional 8–15% body weight loss over 6 months compared to those continuing suboptimal medications. Cost savings also emerge: by finding your ideal therapy quickly, you avoid spending months on ineffective compounds or escalating doses of a medication your genetics predict will never work as well as an alternative.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Precision Peptide Genetic Test starts at $99 add-on. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

I lost weight on Wegovy for 3 months, then it stopped working. Why?

Weight loss plateaus on GLP-1 therapy often signal genetic mismatch rather than medication failure. Your body may have adapted to semaglutide's single GLP-1 receptor activation, or your genetic profile may favor dual-pathway activation (like tirzepatide). PlexusDx's Precision Peptide Genetic Test identifies whether a switch to tirzepatide, GLP-Squared, or dose adjustment within your current compound will restart progress.

What's the difference between PlexusDx compounded GLP-1 and Wegovy?

Both contain active GLP-1 agonists, but PlexusDx medications are compounded by licensed 503A pharmacies and priced flat per formulation (not per dose), allowing flexible dosing without price increases. PlexusDx also integrates genetic testing to guide compound selection, whereas Wegovy is a fixed brand-name dose. PlexusDx serves all 50 states without insurance requirements.

How quickly will I see results after starting PlexusDx therapy?

Most patients experience appetite reduction within 3–7 days and measurable weight loss within 4–8 weeks on genetically-matched therapy. If you add the Precision Peptide Genetic Test in month one, results may accelerate in month two after your therapy is optimized based on your peptide-pathway genetics.

Are compounded GLP-1 medications from PlexusDx safe?

Yes. PlexusDx sources all compounded medications exclusively from licensed 503A compounding pharmacies, which operate under strict FDA oversight and state pharmacy regulations. These facilities follow identical quality and sterility standards as brand-name pharmaceutical manufacturers. You receive the same active ingredients as Wegovy or Mounjaro, with added personalization and affordability.

What does the Precision Peptide Genetic Test actually measure?

PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptide-related genes to predict your response to GLP-1 and GIP receptor agonists. Key variants include GLP1R (receptor sensitivity), GIPR (dual-pathway activation), FTO (fat storage), and MC4R (satiety). This peptide-pathway analysis is not a standard pharmacogenomic test—it's specialized to guide GLP-1 therapy selection for precision weight loss outcomes.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves